AI Tool Comparison
Recursion vs AKASA
An objective side-by-side comparison based on global rankings, AI scores, and monthly user data.
Higher ranked
Recursion
HealthcareAI-enabled drug discovery platform.
AI Score72.5 / 100
#271
Global rank
–
Monthly users
VS
AKASA
HealthcareAI platform for healthcare revenue cycle operations.
AI Score63.4 / 100
#544
Global rank
–
Monthly users
Side-by-Side Comparison
| Recursion | AKASA | |
|---|---|---|
| Category | Healthcare | Healthcare |
| Global Rank | #271 | #544 |
| AI Score | 72.5/100 | 63.4/100 |
| Monthly Users | – | – |
| Pricing | Contact Sales | Contact Sales |
| Website | recursion.com | akasa.com |
Pros & Cons
Recursion
- Large pipeline after the Exscientia merger
- Public reporting
- Cash runway into early 2028
- No approved drug yet
- Large net losses against small revenue
- Details come mostly from secondary sources
AKASA
- Works within existing systems
- Focused on a clear problem area
- Well funded, per aggregators
- Little public customer outcome data
- Series C details are from aggregators only
- No public pricing